Applications for San Francisco (Batch 12) extended through September 15th, 2021!

Learn more about investing in Neurocarrus Inc

Our team will get back to you soon to follow up on your inquiry.
Neurocarrus Inc
Non-opiod pain relief
Founded
2017
Employees*
1-10
Funding to Date*
$100K
Website
neurocarrus.com
Benjamin Pavlik, PhD, CEO
Our success as a company would change the healthcare industry by providing an alternative to opioids as a front-line pain management solution.
More than 11 million people abused prescription opioids in 2016, and the CDC estimates it has an economic cost of $80B a year

Traditionally, people in pain are given Opioids—which, although they relieve pain, can have dangerous side effects such as loss of motor function, and addiction. Ocycontin, Vicodin, and other pain relievers are effective in subduing pain, but they are extremely addictive, which causes major problems in families and communities.

The Opioid Crisis is a reality we’re facing now—but what if pain could be treated another way? That’s exactly what Neurocarrus has been working on. Their new drug delivery technology safely disrupts pain signals without possessing addiction-forming qualities. The company’s lead asset, N-001, is a novel protein that was synthesized to target key sensory neuron structures called actin. It is designed to disrupt peripheral pain signaling without affecting motor function or causing addiction.

Similar Companies

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.